Immune and inflammation confusion in severe sepsis and effects of bi-immunomodulation therapy: a prospective, randomized, controlled clinical trial

• Published in: Zhong hua yi xue za zhi Vol. 89; no. 15; p. 1028
• Main Authors: Zhou, Li-Xin, Tan, Jia-Ju, Li, Yi-Nan, Luo, Hong-Tao, Shao, Yong-Hong, Qiang, Xin-Hua, Yu, Tie-Ou, Ma, Ming-Yuan, Mao, Ke-Jiang, Fang, Bin
• Format: Journal Article
• Language: Chinese
• Published: China 21.04.2009
• Subjects: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Female; Hemofiltration; Humans; Immunity, Cellular; Inflammation; Male; Middle Aged; Prognosis; Prospective Studies; Sepsis - immunology; Sepsis - therapy; Thymosin - analogs & derivatives; Thymosin - therapeutic use
• DOI: 10.3760/cma.j.issn.0376-2491.2009.15.006
• ISSN: 0376-2491

To investigate the immune and inflammation confusion state in severe sepsis and the effects of two way immunomodulation therapy with continuous blood purification (CBP), thymosin alpha1, and combined therapy of CBP and thymosin alpha(1). 91 Patients with severe sepsis aged > 18, with Marshall score>5. were randomly divided into 4 groups: CBP Group (n = 22) undergoing continuous renal replacement therapy (CRRT) or molecular adsorbents recirculating system (MARS) therapy once a day for 3 days in addition to classical Surviving Sepsis Campaign (SSC) therapy, Thymosin alpha(1) Group (n = 23) undergoing subcutaneous injection of thymosin alpha(1) 1.6 mg once a day for 7 days in addition to SSC therapy, Combined Therapy Group (n = 22) undergoing CBP combined with thymosin alpha(1) treatment in addition to SSC therapy, and SSC Group (treatment control group, n = 24) undergoing SSC therapy only. Peripheral blood samples were collected before treatment, and 3 and 7 days after the beginning of treatment (days 4 and 8)